EICHORCondition: Crohn Disease · Remission · Sponsor: Alimentiv Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to assess whether withdrawal of aminosalicylate (5-ASA) is non-inferior to continuation of 5-ASA therapy in Crohn's disease (CD) subjects in remission.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Calgary | Calgary, Alberta, Canada | — |
| University of Alberta | Edmonton, Alberta, Canada | — |
| Dr. Jesse Siffledeen Professional Medical Corporation | Edmonton, Alberta, Canada | — |
| (G.I.R.I.) GI Research Institute | Vancouver, British Columbia, Canada | — |
| Discovery Clinical Services Ltd. | Victoria, British Columbia, Canada | — |
| University of Manitoba - Health Sciences Centre | Winnipeg, Manitoba, Canada | — |
| London Health Sciences Centre - University Hospital | London, Ontario, Canada | — |
| Scott Shulman Medical Professional Corporation | North Bay, Ontario, Canada | — |
| Taunton Surgical Center | Oshawa, Ontario, Canada | — |
| Mount Sinai Hospital | Toronto, Ontario, Canada | — |
| Dr. O. Tarabain Medicine Professional Corporation | Windsor, Ontario, Canada | — |
| McGill University Healthcare | Montreal, Quebec, Canada | — |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03261206